On April 18, 2022 Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, reported the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022 (Press release, Ensysce Biosciences, APR 18, 2022, View Source [SID1234612399]). Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company’s clinical advisory board.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Osman, a highly versatile board-certified neurologist, migraine and pain specialist, has over ten years of experience in both R&D and medical affairs within the pharmaceutical, CRO and medical device industries. Dr. Osman was previously the Senior Medical Director at Scholar Rock where she led their program for spinal muscular atrophy and was a practicing neurologist and academic researcher at the University of Toronto. She recently returned from Poland where she spent several weeks leveraging her medical expertise providing care to Ukrainian refugees. Dr. Osman completed her residency at University of Ottawa in adult neurology and a fellowship in headache pain medicine at the University of Toronto. She received her M.D. degree from Jagellonian Medical College in Poland, and her B.S. from the University of Guelph, Canada.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "It is my pleasure to welcome Nily to the Ensysce team as we progress and expand our clinical trials in the development of our abuse and overdose-protected pain products. She brings significant expertise and a proven track record in pain and pain management. Her experience in neurology, as well as within the pharmaceutical industry, makes her an extremely valuable addition to Ensysce at such an important time in the Company’s history."
Dr. Lynn Kirkpatrick concluded, "I am also extremely grateful for Dr. Schmidt’s contributions to our clinical programs. He has been instrumental in our path towards commercialization, and I look forward to our continued working relationship in his role as Senior VP of Clinical Development."
Dr. Osman added, "I am delighted to have the opportunity to work with Lynn and join the very talented team at Ensysce and be part of the Company’s mission to launch the next generation opioid products. As the Company progresses on its clinical trials, I look forward to leveraging my direct industry experience as I believe this is truly an exciting time to join the Company with several key milestones approaching."